Hints and tips:
...When Paul Bisaro, executive chairman of Actavis, raised the idea of buying Allergan this summer, he prompted some surprise from his company’s board....
...The board will have 15 directors, including all of Pfizer’s 11 directors and four from Allergan, including Paul Bisaro, the company’s executive chairman and the architect behind its transformation from a...
...To begin with, the architect of this shape-shifting strategy was Paul Bisaro , executive chairman....
...Though chief executive Brenton Saunders is now the group’s public face, the architect of the strategy was Paul Bisaro, who stepped up to executive chairman this summer after seven years at the helm....
...Paul Bisaro, the outspoken chief executive of drugs company Actavis, has quickly gained a reputation as an ambitious dealmaker in a competitive drugs market....
...Paul Bisaro, chief executive of Actavis, said: “Bolstered by one of the deepest and most diversified product portfolios in the industry with an exceptionally strong pipeline, this transaction creates a powerful...
...Paul Bisaro, head of Actavis, says: “Given the cost of development, no one will have the money alone. We’ve assumed $200m per biosimilar product, compared with $2m-$15m for a normal generic.”...
...Paul Bisaro, president and chief executive of Actavis, said: “The combination of Actavis and Warner Chilcott creates a strong speciality brand portfolio focused in therapeutic categories with strong growth...
...After acquiring Ireland-incorporated Warner Chilcott, Paul Bisaro, CEO of Actavis, said: “Unfortunately, we have a tax structure in the United States that is putting companies in the US at a disadvantage...
...Paul Bisaro, chairman, said he was focusing on expansion in eastern Europe, southeast Asia and Latin America. He ruled out India and China....
...Paul Bisaro, Watson’s chief executive, said at a conference this month that the company’s cash flow from operations last year was more than $630m....
...Paul Bisaro, president and chief executive of Watson, said: “The acquisition of Actavis will create the third-largest global generics company, substantially completing Watson’s expansion as a leading global...
...Paul Bisaro, Watson’s chief executive, has frequently talked about his appetite for acquisitions in an effort to expand the US group internationally and into biological generic medicines....
...Paul Bisaro, chief executive of Watson and chairman of the Generic Pharmaceutical Association, a trade body, told the Financial Times that the high costs of growing scrutiny by the US Food and Drug Administration...
...“There are a number of actions coming,” says Paul Bisaro, head of Watson, the US generic medicines company. “The probes are causing a lot of people to sit up and take notice.”...
...Paul Bisaro, president of Watson Pharmaceuticals and head of the Generic Pharmaceutical Association, the US trade body, told the FT the industry is effectively “eating our young” with intensifying court...
...In a 14-page ruling issued in a US district court in Washington, Judge Alan Kay said facts presented in court did not support allegations by Watson that the FTC had issued a subpoena of Paul Bisaro, Watson...
...The FTC, which denies wrongdoing, had demanded that Watson’s chief executive, Paul Bisaro, testify on his company’s dealings with Cephalon. Mr Bisaro has resisted the subpoena....
...Paul Bisaro, the chief executive of Watson, says the regulatory pathway created by the law is of no practical use....
International Edition